Collaborations & Alliances

Array BioPharma, Pierre Fabre In Oncology Alliance

To develop Array's late-stage products, binimetinib and encorafenib

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Array BioPharma Inc. and Pierre Fabre have entered a collaboration to globally develop and commercialize Array’s late-stage oncology products, binimetinib and encorafenib. Binimetinib, a MEK inhibitor, and encorafenib, a BRAF inhibitor, are currently in Phase III trials for melanoma and ovarian cancer. The agreement is subject to European Commission review and approval.   Array will receive $30 million upfront and retains exclusive commercialization rights for binimetinib and encorafenib...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters